Ingersoll Rand Inc. (IR) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

we I think I think we're I think we're good I think we're ready to go all right all right our next uh fireside chat is is Ingersoll we're in we're really happy to have Vic Kinney chief financial officer here with us today uh Vic great to see you yeah thanks for having us so I don't know if you want to open up with any initial remarks if you want to get right into Q&A however you want to do this listen why don't we just jump right into it all right perfect why don't why don't we start um look the evolution of Ingersoll has been incredible um The amount of M&A you guys have done over the last four to five years has also been incredible. It's been an important part of the value creation framework going forward. We're still trying to get to know a little bit about this ILC Dover acquisition. So why don't we start there and tell us what the strategy is behind that acquisition, ultimately what that means for your broader medical portfolio as you continue to scale the business. Yeah, absolutely. So, yeah, so let me just start by saying, you know, first and foremost, really excited by kind of the momentum we've seen. We're coming up on close to five years now since the merger to creating or saw RAND. And, you know, one of the biggest opportunities that we saw when we put the companies together was a large fragmented kind of you know, end market base, the opportunity for acquisitions. And, you know, I think one of the big things, and we'll get to ILC Dover here, was that there were a lot of bolt-on, you know, M&A opportunities. And so to set the stage, here we are in, you know, December 2024. I think over the last four and a half plus years, we've done, you know, 55, 56, you know, acquisitions. I would say all largely bolt-on in nature, and maybe ILC Dover slightly larger tha...